3月20日，同仁堂国药（03613）发布截至2025年12月31日止年度业绩，收入为15.13亿港元，同比下降6.1%；毛利为9.26亿港元，同比下降13.1%；归母净利润为3.97亿港元，同比下降20.6%。建议每股普通股末期股息为0.37港元，特别股息为0.03港元。
在财务回顾中，毛利率由66.1%下降至61.2%，主要由于原材料成本增加。分销及销售开支为2.07亿港元，同比下降31.0%，主要是广告及宣传费用减少。一般及行政开支为1.83亿港元，同比减少4.4%。
在业务方面，香港市场收入同比下降11.9%，主要因销售渠道管理优化；中国内地市场收入同比增长18.3%。海外市场收入增长0.9%。整体来看，公司的业务结构和收入来源多样化，有助于应对市场波动和挑战。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.